– AUSTRIA, Vienna – HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Dr. Tim Reilly (Ph.D.) to its Board of Directors, effective immediately.
“We’re pleased to have Tim join our Board as we advance our oncology pipeline of novel arenaviral immunotherapeutics in and towards the clinic. Tim’s experience in product development, especially driving early clinical development that supports eventual marketed products, is enormously relevant to our current focus. We will benefit from his insights on our ongoing Phase 2 HB-200 program for head and neck cancer, our IND preparations for our HB-300 program in prostate cancer and further development of our HB-700 program for KRAS-mutated cancers,” said CEO, Joern Aldag.
About Dr. Tim Reilly
Dr. Tim Reilly currently serves as Chief Development Officer at HotSpot Therapeutics, a biotechnology company pioneering the discovery and development of novel small molecule allosteric therapies directed at natural hotspots for the treatment of cancer and autoimmune disease. Before taking this role in 2021, Tim spent more than 18 years at Bristol Myers Squibb. He last served as Senior Vice President within Research & Early Development, where he was responsible for the early development portfolio across therapeutic areas in oncology, immunology, fibrosis, cardiovascular, and neuroscience. In this capacity, he oversaw the integration of all nonclinical and clinical efforts, starting from the development candidate through Phase 1/2 clinical development. During his time at BMS, he was a contributor to the approval of 12 therapies across a range of diseases, as well as several company acquisitions.
Tim is active in the biotech industry in other capacities; he is a contributor to several biotech companies as an Entrepreneur in Residence through Atlas Ventures, serves as an industry representative to the Network Steering Committee of the Experimental Cancer Medicines Centres at Cancer Research UK, and sits on the Translation Research Council for CureSMA. He also is co-founder and CSO of a non-profit organization, Spinal Muscular Atrophy Research Team (SMART).
“It’s an exciting time to join the HOOKIPA Board of Directors,” said Dr. Tim Reilly. “HOOKIPA’s unique arenaviral platform has already demonstrated clinical impact in head and neck cancer, and the versatility of the platform to target a wide range of cancer antigens, either alone or in combination, creates a lot of exciting opportunities from a development perspective. I’m looking forward to sharing my experiences to help the company make a real impact on cancer.”
Tim earned his undergraduate degree from the University of Notre Dame, did his doctoral training in Pharmaceutical Sciences at Wayne State University, and served as a research fellow at the National Institutes of Health.
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic, and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.
For more information: https://www.hookipapharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.